Skip to main content
Premium Trial:

Request an Annual Quote

An 'Omics Army

The US Army is hopping on the 'omics bandwagon.

Last month, the Army Edgewood Chemical Biological Center and the Army Medical Research Institute opened a new Proteomics Core Facility, which will serve as a resource for both institutions offering expanded proteomic and genomic capabilities.

According to a release from the ECBC, the organizations will use the facility for work in areas including whole genome sequencing and whole transcriptome analysis as well as mass spec-based proteomics.

The facility will also be used by the Defense Threat Reduction Agency/Joint Science and the Technology Chemical and Biological Defense Program for work on protecting military personnel from the chemical and biological warfare agents.

This isn't the army's first foray into the 'omics world, of course. For instance, in April, researchers at Arizona State University's Biodesign Institute won $30 million from the Department of Defense to build a prototype of a proteomics-based chip that can be used in the field for monitoring subjects' health and early detection of pathogen infection.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.